RBM39

Across TCGA pan-cancer cohorts, RBM39 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RBM39 data layer compared with 29 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RBM39 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated RBM39 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, DLBC, and SKCM are the cancer types where RBM39 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.933	0.539	.018	14	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
SKCM	DFS	Median	All	0.087	0.757	<.001	9	view →
KIRC	DFS	Median	All	0.139	0.627	.020	6	view →
ESCA	OS	Median	All	0.222	0.680	.031	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
BLCA	DFS	Median	III,IV	0.771	0.426	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RBM39–UCEC (OS)

Open the UCEC breakdown →